In addition to the recently issued US patents, the company was granted: AU 2004241093, corresponding to US Patent No 7,569,554, entitled ‘Synergistic Treatment of Cancer Using Immunomers in Conjunction with Therapeutic Agents;’ AU 2005222909.
Additionally, it has also received AU 2005222909 corresponding to US Patent Application No 11/078,654, entitled ‘Enhanced Activity of HIV Vaccine Using a Second Generation Immunomodulatory Oligonucleotide;’ JP 4443810, corresponding to US Patent No 6,815,429, entitled ‘Modulation of Oligonucleotide CpG-Mediated Immune Stimulation by Positional Modification of Nucleosides,’ and MK 903127, corresponding to US Patent Application No 11/153,054, entitled ‘Immunostimulatory Oligonucleotide Multimers.’
Idera Pharma’s intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, antisense chemistry, and oral delivery of certain oligonucleotides.